Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Fax: 31 71 524 7445

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

BiotechBonesaw Jul. 10 at 5:04 PM

$KALV ‘s gain is $PHAR loss. 📊

0 · Reply

Ruconestor Jul. 7 at 1:33 PM

$PHAR Dan weet je toch genoeg . Ruconest( c1 inhibitor )is het Breedste veiligste , snelste en best werkende middel tot nu toe voor behandeling HAE

0 · Reply

Ruconestor Jul. 7 at 1:26 PM

$PHAR 4. Duur en beschikbaarheid • Lanadelumab (Takhzyro), een monoklonaal antilichaam tegen plasma-kallikreïne, is zeer duur en kan logistiek uitdagender zijn in vergelijking met C1-INH-producten, die al langer op de markt zijn. • Niet alle kalikreïneremmers zijn wereldwijd beschikbaar of vergoed. ⸻ 5. Langetermijndata • C1-inhibitoren hebben een langer track record qua veiligheid en effectiviteit. • Kalikreïneremmers zijn relatief nieuw (bijv. lanadelumab sinds 2018) en hoewel studies positief zijn, is er minder langetermijnervaring.

0 · Reply

Ruconestor Jul. 7 at 1:24 PM

$PHAR ⸻ 2. Geen effect bij andere vormen van HAE • Kalikreïneremmers zijn vooral effectief bij HAE type I en II (bradykinine-gemedieerd). • Ze zijn mogelijk minder bruikbaar bij HAE met normale C1-INH (zgn. nC1-INH-HAE), waar de pathogenese anders kan zijn. ⸻ 3. Immuunreacties/allergieën (bij bepaalde middelen) • Bij ecallantide (een subcutane kallikreïneremmer) bestaat een risico op anafylaxie (~3%), wat betekent dat het alleen onder medische supervisie mag worden toegediend. • Dit risico bestaat niet bij C1-inhibitorpreparaten.

0 · Reply

Ruconestor Jul. 7 at 1:21 PM

$PHAR Nadeel van een kalikreïneremmer t.o.v. een C1-inhibitor Hoewel kalikreïneremmers effectief zijn bij het voorkomen van aanvallen van HAE, zijn er een aantal nadelen ten opzichte van C1-inhibitoren: ⸻ 1. Beperkter werkingsmechanisme • C1-inhibitoren grijpen breder in op het complement- en contactactivatiesysteem (waaronder C1, kallikreïne en factor XIIa), en richten zich op de onderliggende oorzaak van HAE type I en II. • Kalikreïneremmers blokkeren slechts één stap in de keten: de omzetting van hoog-moleculair-gewicht-kininogeen (HMWK) naar bradykinine via kallikreïne. Ze pakken dus een downstream-gevolg aan, niet de primaire deficiëntie. ➡️ Gevolg: Bij sommige patiënten kan dit betekenen dat C1-INH effectiever is, vooral bij acute aanvallen. ⸻

0 · Reply

Ruconestor Jun. 30 at 3:36 PM

$PHAR Again excellent results for far more leniolisib patients.this stock Will explode . So much more VUS is so much more pharming medication.

1 · Reply

More_Rockets Jun. 27 at 11:29 AM

$PHAR Any views from anyone regarding any pro/cons of owning Pharming stock via Amsterdam exhange versus Nasdaq? I bought $PHARM using IBKR traded on AEB, then noticed only afterwards that it's traded on Nasdaq as $PHAR.

0 · Reply

Ruconestor Jun. 24 at 6:30 AM

$PHAR Excellent News on Leniolisib ( Joenja) Much more patients APDS will be defined. That will boost this stock ! Pharming will 🚀 up

1 · Reply

Noobnr1 Jun. 10 at 9:43 AM

$CRSP $GILD $PFE $PHAR $DVAX Now is the time to shine 🤩🚀💎🌪️

0 · Reply

BiotechBonesaw Jun. 9 at 2:03 PM

$KALV - Kalvista is still a buy ahead of their PDUFA $PHVS - Pharvaris is a hold well ahead of their HAE activity in 2026 $PHAR - I would sell or avoid this. Pharming will likely lose market shares or valuation with Kalvista’s expected approval & continued rise

1 · Reply

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 11, 2025, 11:15 AM EDT - 5 weeks ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

May 28, 2025, 2:00 AM EDT - 7 weeks ago

Pharming Group to participate in June investor conferences

May 9, 2025, 8:50 AM EDT - 2 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 2 months ago

Pharming Group reports first quarter 2025 financial results and provides business update

Apr 30, 2025, 11:45 AM EDT - 2 months ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 24, 2025, 2:00 AM EDT - 3 months ago

Pharming Group to report first quarter 2025 financial results on May 8

Apr 23, 2025, 3:30 AM EDT - 3 months ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 3, 2025, 1:00 AM EDT - 3 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Mar 28, 2025, 3:00 AM EDT - 3 months ago

Pharming Group to participate in April investor conferences

Mar 13, 2025, 7:44 PM EDT - 4 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 4 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 4, 2025, 9:15 AM EST - 4 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Feb 7, 2025, 4:00 PM EST - 5 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Jan 21, 2025, 12:00 PM EST - 6 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 1:00 AM EST - 6 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Dec 15, 2024, 1:45 PM EST - 7 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 11, 2024, 9:34 AM EST - 7 months ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Nov 5, 2024, 2:00 AM EST - 9 months ago

Pharming Group to participate in November investor conference

Oct 24, 2024, 1:44 PM EDT - 9 months ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 10, 2024, 2:00 AM EDT - 10 months ago

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 1:00 AM EDT - 10 months ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Sep 26, 2024, 1:00 AM EDT - 10 months ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 4, 2024, 1:00 AM EDT - 11 months ago

Pharming Group to participate in September investor conferences

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 8, 2024, 1:00 AM EDT - 1 year ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 4, 2024, 2:30 AM EDT - 1 year ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Apr 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Mar 14, 2024, 1:15 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 2:00 AM EDT - 1 year ago

Pharming Group reports fourth quarter and full year 2023 financial results

Feb 29, 2024, 2:00 AM EST - 1 year ago

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Feb 8, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in February investor conferences

Jan 8, 2024, 1:00 AM EST - 1 year ago

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Dec 13, 2023, 1:00 AM EST - 1 year ago

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Nov 10, 2023, 8:51 AM EST - 1 year ago

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Nov 7, 2023, 2:00 AM EST - 1 year ago

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Nov 1, 2023, 3:00 AM EDT - 1 year ago

Pharming Group to participate in November investor conferences

Oct 27, 2023, 8:35 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript

BiotechBonesaw Jul. 10 at 5:04 PM

$KALV ‘s gain is $PHAR loss. 📊

0 · Reply

Ruconestor Jul. 7 at 1:33 PM

$PHAR Dan weet je toch genoeg . Ruconest( c1 inhibitor )is het Breedste veiligste , snelste en best werkende middel tot nu toe voor behandeling HAE

0 · Reply

Ruconestor Jul. 7 at 1:26 PM

0 · Reply

Ruconestor Jul. 7 at 1:24 PM

0 · Reply

Ruconestor Jul. 7 at 1:21 PM

0 · Reply

Ruconestor Jun. 30 at 3:36 PM

$PHAR Again excellent results for far more leniolisib patients.this stock Will explode . So much more VUS is so much more pharming medication.

1 · Reply

More_Rockets Jun. 27 at 11:29 AM

0 · Reply

Ruconestor Jun. 24 at 6:30 AM

$PHAR Excellent News on Leniolisib ( Joenja) Much more patients APDS will be defined. That will boost this stock ! Pharming will 🚀 up

1 · Reply

Noobnr1 Jun. 10 at 9:43 AM

$CRSP $GILD $PFE $PHAR $DVAX Now is the time to shine 🤩🚀💎🌪️

0 · Reply

BiotechBonesaw Jun. 9 at 2:03 PM

1 · Reply

BiotechBonesaw Jun. 3 at 2:47 PM

$PHAR surprised this is running up ahead of $KALV approval in HAE. GLL biotech investors but I would avoid PHAR $ $PHVS until Kalvista does their thing

1 · Reply

Dutchindo Jun. 3 at 8:18 AM

$PHAR 52 wk high 📈

0 · Reply

PenkeTrading May. 9 at 4:10 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Pharming Group NV. Is that bullish or bearish? $PHAR #Pharming #RsiOverbought #NASDAQ

0 · Reply

SannieVerraderlijk May. 8 at 8:54 AM

$PHAR https://www.globenewswire.com/news-release/2025/05/08/3076806/0/en/Pharming-Group-reports-first-quarter-2025-financial-results-and-provides-business-update.html

0 · Reply

SannieVerraderlijk May. 8 at 8:54 AM

$PHAR Great earnings, buy now premarket if you can. Up 17% in Europe

1 · Reply

Declan1NL May. 8 at 8:05 AM

$PHAR It will explot to day 42% more profit

1 · Reply

Armonica423 May. 7 at 1:53 AM

$PHAR CYDY

0 · Reply

Bamster Apr. 28 at 4:35 PM

Long term for me: $OMEX extract minerals from the sea. We are getting a shorter everyday. With approval of the 🍊 guy $QBTS quantum, do I need to say more?💾 $ASML without this company no minuscule chips🍪 and the best machines for this $PHAR got some nice drugs trails drug💊 $MBRX possibility for cancer treatment. 👨‍🦲

0 · Reply

Thestocktraderhubzee Apr. 23 at 9:56 AM

WATCHLIST APR 23 2025 $TOI The Oncology Institute Announces Enterprise-wide Expansion Of Strategic Partnership With Helios Clinical Research $SNOA Sonoma Pharmaceuticals shares are trading higher after the company announced the registration and launch of new products in the UK. $CSCO Rosenblatt Maintains Buy on Cisco Systems, Lowers Price Target to $63 $PHAR Pharming Group Announces That The National Institute For Health And Care Excellence (Nice) Has Issued Positive Final Guidance Recommending Joenja (Leniolisib) Within The National Health Service In England And Wales For The Treatment Of Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) $FICO FICO And Dacadoo Have Partnered To Enhance The Way Insurance Companies Can Assess And Manage Risk, Promote Health/Wellness, And Improve Customer Engagement

0 · Reply

SannieVerraderlijk Apr. 23 at 8:00 AM

$PHAR Up she goes https://www.globenewswire.com/news-release/2025/04/23/3066101/0/en/Pharming-receives-positive-recommendation-from-NICE-for-Joenja-leniolisib-as-a-treatment-for-APDS.html

0 · Reply

LewisDaKat Apr. 4 at 7:25 PM

$PHAR News Article Objective long/short (PHAR) Report https://marketwirenews.com/news-releases/objective-long-short-phar-report-7428609299406215.html $PHAR

0 · Reply

Noobnr1 Mar. 21 at 6:46 PM

$PHAR 🚀🚀🚀🚀 $DVAX $PFE $GILD 🙏🚀🚀🙏 🥳🍾🥳🍾

0 · Reply

Market Cap	692.34M
Revenue (ttm)	297.20M
Net Income (ttm)	-11.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.98%
Debt to Equity Ratio	0.02

Volume	700
Avg Vol	3,504
Day's Range	N/A - N/A
Shares Out	68.52M
Stochastic %K	46%
Beta	0.02
Analysts	Strong Sell
Price Target	$30.33